Research Topics
| G D'HaensSummaryAffiliation: Imelda Hospital Country: Belgium Publications
| Collaborators
|
Detail Information
Publications
Advances in medical therapy for Crohn's diseaseGeert D'Haens
Department of Gastroenterology, University of Leuven, Herestraat 49, 3000 Leuven, Belgium
Curr Gastroenterol Rep 4:506-12. 2002..In fistulizing disease, infliximab is becoming the treatment of choice, although fistula tracks do not disappear permanently and many patients still need surgical intervention...- Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging studyG D'Haens
Department of Gastroenterology, Imelda General Hospital, Imelda GI Clinical Research Center, Imeldalaan, Bonheiden, Belgium
Aliment Pharmacol Ther 24:1087-97. 2006..SPD476 (MMX mesalazine), is a novel, once daily, high-strength mesalazine formulation (1.2 g/tablet) that utilizes Multi Matrix System (MMX) technology to delay and extend delivery of the active drug throughout the colon... 
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trialGeert R D'Haens
Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
Gastroenterology 135:1123-9. 2008..Goal: We sought to examine whether metronidazole for 3 months together with azathioprine (AZA) for 12 months is superior to metronidazole alone to reduce recurrence of postoperative CD in "high-risk" patients...- Top-down therapy for IBD: rationale and requisite evidenceGeert R D'Haens
Imelda GI Clinical Research Center, Imeldalaan 9, 2820 Bonheiden, Belgium
Nat Rev Gastroenterol Hepatol 7:86-92. 2010..Identification of suitable patients, however, remains a challenge, as genetic, phenotypic and environmental factors have not yet been identified that can be used for routine assessment and selection is mainly based on clinical criteria... - Anti-TNF-alpha treatment strategies: results and clinical perspectivesG D'Haens
Imelda GI Clinical Research Centre, Imelda General Hospital, Imeldalaan 9, 2820 Bonheiden, Belgium
Gastroenterol Clin Biol 33:S209-16. 2009..There is a clear tendency to use anti TNF therapy earlier in the course of inflammatory bowel disease, but predictive markers to select patients who really need these therapies are urgently needed... - Top-down therapy for Crohn's disease: rationale and evidenceG R D'Haens
Imelda GI Clinical Research Centre, Bonheiden, Belgium
Acta Clin Belg 64:540-6. 2009..The key to successful management of Crohn's disease appears to lie in careful timing and selection of the appropriate interventions... - Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's diseaseGeert R D'Haens
Irnelda GI Clinical Research Center, Bonheiden, Belgium
Inflamm Bowel Dis 15:1599-604. 2009..The proposed instruments will need further validation and standardization to demonstrate that they are reliable in stable disease and responsive to change, and to determine the cutoff points for response and remission... - Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialGeert D'Haens
Imelda Gastrointestinal Clinical Research Centre, Bonheiden, Belgium
Lancet 371:660-7. 2008..We aimed to compare the effectiveness of early use of combined immunosuppression with conventional management in patients with active Crohn's disease who had not previously received glucocorticoids, antimetabolites, or infliximab... - A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitisWilliam J Sandborn
University Hospital Gasthuisberg, Leuven, Belgium
Gastroenterology 132:763-86. 2007 - Advances in biologic therapy for ulcerative colitis and Crohn's diseaseGeert D'Haens
Imelda GI Clinical Research Center, Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium
Curr Gastroenterol Rep 8:506-12. 2006..Only the chimeric monoclonal anti-TNF antibody infliximab is currently available worldwide. The potency of this agent in moderate-to-severe UC and CD has been one of the most important advances in the care of IBD in the past decade... - Advances in medical therapy for Crohn's diseaseGeert D'Haens
Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium
Curr Gastroenterol Rep 6:496-505. 2004..Extracorporeal apheresis and even stem cell transplantation were found to be effective in isolated patients, but these therapies warrant further prospective and controlled investigation... - Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's diseaseFilip Baert
Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
Gastroenterology 138:463-8; quiz e10-1. 2010..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease... - Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trialG D'Haens
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Gastroenterology 116:1029-34. 1999..Tumor necrosis factor (TNF) is a pivotal cytokine in intestinal inflammation. Controlled trials using a chimeric anti-TNF antibody (infliximab) have shown its efficacy in refractory Crohn's disease... - Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitisG D'Haens
Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
Gastroenterology 120:1323-9. 2001..We investigated the effects of intravenous (IV) cyclosporine as single IV therapy (without glucocorticosteroids) for severe UC and compared these with the response to glucocorticosteroids... - Quality assurance and recommendations for quality assessment of screening colonoscopy in BelgiumE Macken
Department of Gastroenterology, UZ Antwerp, Belgium
Acta Gastroenterol Belg 72:17-25. 2009..Our goal of this update is to provide practical guidelines for endoscopists performing screening colonoscopy. We hope to provide a broad consensus and an increasing adherence to these recommendations... - Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitisSofie Joossens
Department of Gastroenterology, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium
Clin Chem 50:1422-5. 2004 - A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitisScott Plevy
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA
Gastroenterology 133:1414-22. 2007.... - Biological therapy in the management of recent-onset Crohn's disease: why, when and how?Mark Lowenberg
Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
Drugs 66:1431-9. 2006..Further research will have to determine whether corticosteroid therapy augments the mechanism of loss of tolerance in Crohn's disease, which could complicate future clinical management... - Rapid immunosuppressive effects of glucocorticoids mediated through Lck and FynMark Lowenberg
Laboratory of Experimental Internal Medicine, Academic Medical Center, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
Blood 106:1703-10. 2005..These results identify the inhibition of Lck and Fyn kinases as rapid targets of GCs, mediated via a GC receptor-dependent pathway... - Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's diseaseMark Lowenberg
Laboratory of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
J Immunol 175:2293-300. 2005..Our observations indicate that c-Raf inhibitors are prime candidates for the treatment of CD... - A role for STAT5 in steroid-resistant UC?Mark Lowenberg
Inflamm Bowel Dis 12:665. 2006